MGMT and glioblastoma: [31] devised a multifaceted approach to enhance the efficacy of CRISPR/Cas9-based therapy targeting the O6-methylguanine-DNA methyltransferase (MGMT) gene, a key player in temozolomide (TMZ) resistance in GBM.